abstract |
The present invention relates to use of one or more interferon lambdas (IFN-λs), also known as IL-29 and IL28a/b, for alleviating or preventing viral-induced exacerbation of a respiratory disorder, especially for example exacerbation of asthma arising from viral infection, most commonly rhino virus infection. |